Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma

NCT02112175 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02112175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02112175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2014
Completion date
October 12, 2020
Enrollment
46 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma